In last trading session, The Chemours Company (NYSE:CC) saw 0.61 million shares changing hands with its beta currently measuring 2.01. Company’s recent per share price level of $36.16 trading at $0.09 or 0.25% at ring of the bell on the day assigns it a market valuation of $5.84B. That closing price of CC’s stock is at a discount of -7.49% from its 52-week high price of $38.87 and is indicating a premium of 35.56% from its 52-week low price of $23.30. Taking a look at company’s average trading volume of 1.32 million if we extend that period to 3-months.
For The Chemours Company (CC), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.10. Splitting up the data highlights that, out of 14 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0.93 in the current quarter.
The Chemours Company (NYSE:CC) trade information
Upright in the green during last session for gaining 0.25%, in the last five days CC remained trading in the green while hitting it’s week-highest on Thursday, 01/13/22 when the stock touched $36.16 price level, adding 1.44% to its value on the day. The Chemours Company’s shares saw a change of 7.75% in year-to-date performance and have moved 0.36% in past 5-day. The Chemours Company (NYSE:CC) showed a performance of 10.92% in past 30-days.
Wall Street analysts have assigned a consensus price target of $41.58 to the stock, which implies a rise of 13.04% to its current value. Analysts have been projecting $35.00 as a low price target for the stock while placing it at a high target of $54.00. It follows that stock’s current price would drop -49.34% in reaching the projected high whereas dropping to the targeted low would mean a gain of 3.21% for stock’s current value.
The Chemours Company (CC) estimates and forecasts
Statistics highlight that The Chemours Company is scoring comparatively higher than the scores of other players of the relevant industry. The company added 17.10% of value to its shares in past 6 months, showing an annual growth rate of 104.04% while that of industry is 18.80. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 52.50% in the current quarter and calculating 39.40% increase in the next quarter. This year revenue growth is estimated to rise 27.70% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.57 billion for the same. And 3 analysts are in estimates of company making revenue of $1.59 billion in the next quarter that will end on Mar 2022. Company posted $1.34 billion and $1.4 billion of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 17.10% while estimating it to be 13.50% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 36.00% during past 5 years. In 2022, company’s earnings growth rate is likely to be around 517.30% while estimates for its earnings growth in next 5 years are of 27.00%.
The Chemours Company is more likely to be releasing its next quarterly report between February 09 and February 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
The Chemours Company (NYSE:CC)’s Major holders
Insiders are in possession of 0.97% of company’s total shares while institution are holding 78.46 percent of that, with stock having share float percentage of 79.23%. Investors also watch the number of corporate investors in a company very closely, which is 78.46% institutions for The Chemours Company that are currently holding shares of the company. FMR, LLC is the top institutional holder at CC for having 16.05 million shares of worth $466.3 million. And as of Sep 29, 2021, it was holding 9.85% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 15.92 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 9.77% of outstanding shares, having a total worth of $462.72 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Core S&P Midcap ETF are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 4.7 million shares of worth $136.72 million or 2.89% of the total outstanding shares. The later fund manager was in possession of 4.45 million shares on Oct 30, 2021, making its stake of worth around $124.75 million in the company or a holder of 2.73% of company’s stock.